Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics

Alnylam Pharmaceuticals, Inc. (ALNY): $182.61

1.87 (+1.03%)

POWR Rating

Component Grades













Add ALNY to Watchlist
Sign Up

Industry: Biotech


of 476

in industry


  • ALNY scores best on the Growth dimension, with a Growth rank ahead of 74.18% of US stocks.
  • The strongest trend for ALNY is in Quality, which has been heading up over the past 52 weeks.
  • ALNY ranks lowest in Momentum; there it ranks in the 8th percentile.

ALNY Stock Summary

  • ALNY's price/sales ratio is 28.85; that's higher than the P/S ratio of 92.76% of US stocks.
  • With a year-over-year growth in debt of 130.82%, Alnylam Pharmaceuticals Inc's debt growth rate surpasses 92.56% of about US stocks.
  • As for revenue growth, note that ALNY's revenue has grown 86.87% over the past 12 months; that beats the revenue growth of 92.08% of US companies in our set.
  • Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are QRVO, GNTX, IPGP, BGNE, and WDC.
  • ALNY's SEC filings can be seen here. And to visit Alnylam Pharmaceuticals Inc's official web site, go to

ALNY Valuation Summary

  • ALNY's price/earnings ratio is -27; this is 173.97% lower than that of the median Healthcare stock.
  • ALNY's EV/EBIT ratio has moved down 28.4 over the prior 210 months.
  • Over the past 210 months, ALNY's price/sales ratio has gone down 400.7.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2021-08-31 34.8 28.1 -27.0 -31.5
ALNY 2021-08-30 35.2 28.3 -27.3 -31.8
ALNY 2021-08-27 35.3 28.4 -27.3 -31.9
ALNY 2021-08-26 35.0 28.2 -27.1 -31.6
ALNY 2021-08-25 35.4 28.5 -27.5 -32.0
ALNY 2021-08-24 34.9 28.1 -27.1 -31.6

ALNY Growth Metrics

  • Its 5 year price growth rate is now at 143.95%.
  • The 3 year revenue growth rate now stands at 188.59%.
  • Its 3 year cash and equivalents growth rate is now at 213.46%.
ALNY's revenue has moved up $646,437,000 over the prior 67 months.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 687.534 -590.986 -886.681
2021-03-31 570.943 -604.46 -876.351
2020-12-31 492.853 -614.961 -858.281
2020-09-30 400.972 -687.797 -890.926
2020-06-30 345.18 -760.103 -846.17
2020-03-31 285.932 -336.078 -886.422

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
  • ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
  • QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.220 0.833 -0.249
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.64 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $182.61 52-week high $212.00
Prev. close $180.74 52-week low $121.97
Day low $179.08 Volume 267,869
Day high $185.37 Avg. volume 632,779
50-day MA $187.87 Dividend yield N/A
200-day MA $167.99 Market Cap 21.84B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio

Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.

ALNY Latest News Stream

Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream

Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

What Analysts Were Expecting After Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell -0.14%

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shares, rose in value on Friday, 11/26/21, with the stock price down by -0.14% to the previous days close as strong demand from buyers drove the stock to $188.53. Actively observing the price movement in the last trading, the stock closed the session at $188.80, falling within a range of $185.65 What Analysts Were Expecting After Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell -0.14% Read More »

Stocks Register | November 27, 2021

Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a neutral rating to a buy rating in a research note published on Monday, reports. The firm currently has $273.00 price objective on the biopharmaceutical companys stock. A number of other equities research analysts have also weighed in on ALNY. Barclays boosted their []

Transcript Daily | November 25, 2021

Needham & Company LLC Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $205.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective upped by Needham & Company LLC from $180.00 to $205.00 in a research note issued to investors on Monday morning, The Fly reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. HC Wainwright […]

Dakota Financial News | November 25, 2021

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., November 23, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:

Yahoo | November 23, 2021

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

Yahoo | November 23, 2021

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo 14.45%
3-mo -7.32%
6-mo 23.98%
1-year 40.57%
3-year 125.00%
5-year 339.18%
YTD 40.50%
2020 12.85%
2019 57.96%
2018 -42.61%
2017 239.34%
2016 -60.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7424 seconds.